Brokerages Set argenx SE (NASDAQ:ARGX) Price Target at $639.78

Shares of argenx SE (NASDAQ:ARGX) have been given a consensus rating of “Moderate Buy” by the twenty-two ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $639.78.

Several brokerages have weighed in on ARGX. Raymond James reiterated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Wedbush reiterated an “outperform” rating and issued a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective for the company in a research report on Tuesday, November 12th. Oppenheimer restated an “outperform” rating and issued a $675.00 target price (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. Finally, JPMorgan Chase & Co. boosted their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th.

Institutional Investors Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its holdings in shares of argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after purchasing an additional 62 shares in the last quarter. Cromwell Holdings LLC raised its position in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC lifted its stake in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after buying an additional 56 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in argenx during the 2nd quarter valued at $76,000. Finally, Keudell Morrison Wealth Management purchased a new position in argenx during the third quarter worth $207,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $629.99 on Monday. argenx has a 1-year low of $349.86 and a 1-year high of $644.97. The stock has a market cap of $38.03 billion, a P/E ratio of -715.90 and a beta of 0.59. The firm has a fifty day moving average price of $596.43 and a 200 day moving average price of $528.63.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the prior year, the firm earned ($1.25) earnings per share. Sell-side analysts expect that argenx will post 2.2 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.